<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860173</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1525</article-id><article-id pub-id-type="other">EPV0928</article-id><article-id pub-id-type="pii">S0924933824015256</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Metabolic syndrome in psychiatric patients with schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bakija</surname><given-names>I.</given-names></name><xref rid="aff3338" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1374" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tripkovi&#x00107;</surname><given-names>M.</given-names></name><xref rid="aff3339" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ka&#x00161;telan</surname><given-names>S.</given-names></name><xref rid="aff3340" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bogadi</surname><given-names>M.</given-names></name><xref rid="aff3341" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gro&#x00161;i&#x00107;</surname><given-names>V.</given-names></name><xref rid="aff3338" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff3338"><sup>1</sup>Department of Integrative Psychiatry, <institution>Psychiatry Clinic Sveti Ivan</institution></aff><aff id="aff3339"><sup>2</sup>Department of Psychiatry and Psychological Medicine, <institution>University Hospital Centre Zagreb</institution></aff><aff id="aff3340"><sup>3</sup>Department of ophthalmology, <institution>Clinical Hospital Dubrava</institution></aff><aff id="aff3341"><sup>4</sup>Psychiatric Hospital for children and adolescents, <city>Zagreb</city>, <country>Croatia</country></aff><author-notes><corresp id="cor1374"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1500">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S733</fpage><lpage>S734</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015256a.pdf"/><abstract><sec id="sec8260"><title>Introduction</title><p>Metabolic syndrome and cardiovascular diseases are a very important cause of morbidity and mortality among patients with schizophrenia who live an average of 10-20 years less than the general population. Second generation antipsychotics are associated with obesity and other components of the metabolic syndrome.</p></sec><sec id="sec8261"><title>Objectives</title><p>The aim of this paper was to provide complete insight into the existing recent evidence for metabolic risks associated with the use of new antipsychotics, and establish recommendations for monitoring metabolic syndrome and other risks, as well as current options for treatment and prevention of metabolic syndrome.</p></sec><sec id="sec8262"><title>Methods</title><p>This review article is based on a literature search. We identified relevant publications and articles by searching the PUBMED database from 1999 to the present day according to the given parameters. The search criteria were the keywords &#x0201c;metabolic syndrome&#x0201d; combined with &#x0201c;schizophrenia&#x0201d; and &#x0201c;new antipsychotics&#x0201d;.</p></sec><sec id="sec8263"><title>Results</title><p>All researches has convincingly shown that patients with schizophrenia tend to be overweight and have a three to four times higher risk of developing diabetes than the general population. There are also more and more evidence in recent literature about the impact of new antipsychotics on the frequency of metabolic syndrome in patients with schizophrenia.&#x000a0;The World Health Organization (WHO) defines metabolic syndrome as an elevated insulin level or a fasting glucose concentration of 5.6-6.0 mmol/l in combination with two or more of the following parameters: abdominal or central obesity and dyslipidemia and/or arterial hypertension.&#x000a0;The research results systematically showed a 1.5 to 3 times higher frequency of metabolic syndrome in people suffering from schizophrenia compared to the general population. Therefore, regular control of all components of the metabolic syndrome is necessary, from waist circumference, which is the easiest to measure, to all others that can be carried out and done in the general practice doctor&#x02019;s office.</p></sec><sec id="sec8264"><title>Conclusions</title><p>Metabolic changes in patients with shizophrenia who receive new antipsychotics in addition to their unfavorable lifestyle (improper diet, lack of physical activity, smoking) can lead to the development of metabolic syndrome and increase the risk for diabetes and cardiovascular diseases. It is therefore necessary to establish protocols for monitoring these risks and preventing comorbidities.</p></sec><sec id="sec8265"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>